Is Fredun Pharma overvalued or undervalued?

As of 5 February 2025, Fredun Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently fairly valued. Key ratios include a PE ratio of 18.34, an EV to EBITDA of 9.18, and a PEG ratio of 0.69, which suggests that while the company is performing well, it may not be as undervalued as previously thought.
In comparison to peers, Fredun Pharma's PE ratio aligns closely with the industry average, while its EV to EBITDA is also competitive. Notable peers in the pharmaceuticals and biotechnology sector include companies with similar or slightly better ratios, reinforcing the notion that Fredun Pharma is in line with market expectations. Additionally, the company's recent stock performance has outpaced the Sensex over the past week and month, although it has underperformed over the longer term, which may influence investor sentiment moving forward.